Cargando…

Hypoglycemia at the time of Covid-19 pandemic

BACKGROUND: Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Kiran, Tiwaskar, Mangesh, Chawla, Purvi, Kale, Mayura, Deshmane, Rajesh, Sowani, Alpana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Diabetes India. Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347476/
https://www.ncbi.nlm.nih.gov/pubmed/32668399
http://dx.doi.org/10.1016/j.dsx.2020.07.003
_version_ 1783556592828940288
author Shah, Kiran
Tiwaskar, Mangesh
Chawla, Purvi
Kale, Mayura
Deshmane, Rajesh
Sowani, Alpana
author_facet Shah, Kiran
Tiwaskar, Mangesh
Chawla, Purvi
Kale, Mayura
Deshmane, Rajesh
Sowani, Alpana
author_sort Shah, Kiran
collection PubMed
description BACKGROUND: Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food, outpatient clinics, pathological services and medicines. AIM: To assess the factors associated with the risk of hypoglycemia during April–May 2020 lockdown in people with type 2 diabetes mellitus. METHODOLOGY: We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM) reporting to the emergency department (ED) during lockdown period with symptoms suggestive of hypoglycemia. RESULTS: The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value (50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU (60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ) 400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%, and 32.88%) respectively. CONCLUSION: The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities. Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia.
format Online
Article
Text
id pubmed-7347476
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Diabetes India. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73474762020-07-10 Hypoglycemia at the time of Covid-19 pandemic Shah, Kiran Tiwaskar, Mangesh Chawla, Purvi Kale, Mayura Deshmane, Rajesh Sowani, Alpana Diabetes Metab Syndr Article BACKGROUND: Hypoglycemia is the limiting factor in the glycemic management of diabetes, which need to be addressed critically to avoid complications. Lockdown because of new coronavirus strain (COVID-19) pandemic has further complicated the issue of hypoglycemia due to limitations in access to food, outpatient clinics, pathological services and medicines. AIM: To assess the factors associated with the risk of hypoglycemia during April–May 2020 lockdown in people with type 2 diabetes mellitus. METHODOLOGY: We analyzed the data retrospectively from 146 patients of type 2 diabetes mellitus (T2DM) reporting to the emergency department (ED) during lockdown period with symptoms suggestive of hypoglycemia. RESULTS: The majority of patients were male (90/146) with a mean age of 59.88 ± 10.09 years and a mean random blood glucose level of 57.67 ± 9.00 mg/dL. Two-third of patients (70.83%) had level 1 hypoglycemia, while level 2 hypoglycemia was reported in 29.16% of patients. A combination of Metformin and Sulfonylureas (SU) was most commonly associated with the risk of hypoglycemia (65.75%) followed by insulin (33.56%). Subjects who received insulin reported a lower blood glucose value (50.75 ± 8.20 mg/dL) as compared to those receiving a combination of metformin and SU (60.95 ± 7.10 mg/dl). 330.56% of patients who had received prophylaxis hydroxychloroquine (HCQ) 400 mg twice a day along with the routine anti-hyperglycemic agents without their dose adjustment reported hypoglycemia. Patients with hypertension, micro-vascular, macro-vascular complications, and coexistent with each other had a higher propensity to the risk of hypoglycemia (46.58%, 33.56%, 23.29%, and 32.88%) respectively. CONCLUSION: The COVID-19 lockdown has shown to influence the risk of hypoglycemia in patients with T2DM, especially those receiving SU, insulin, HCQ especially in patients with associated co-morbidities. Patient education, support, and telemedicine plays a pivotal role to prevent hypoglycemia. Diabetes India. Published by Elsevier Ltd. 2020 2020-07-10 /pmc/articles/PMC7347476/ /pubmed/32668399 http://dx.doi.org/10.1016/j.dsx.2020.07.003 Text en © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Shah, Kiran
Tiwaskar, Mangesh
Chawla, Purvi
Kale, Mayura
Deshmane, Rajesh
Sowani, Alpana
Hypoglycemia at the time of Covid-19 pandemic
title Hypoglycemia at the time of Covid-19 pandemic
title_full Hypoglycemia at the time of Covid-19 pandemic
title_fullStr Hypoglycemia at the time of Covid-19 pandemic
title_full_unstemmed Hypoglycemia at the time of Covid-19 pandemic
title_short Hypoglycemia at the time of Covid-19 pandemic
title_sort hypoglycemia at the time of covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347476/
https://www.ncbi.nlm.nih.gov/pubmed/32668399
http://dx.doi.org/10.1016/j.dsx.2020.07.003
work_keys_str_mv AT shahkiran hypoglycemiaatthetimeofcovid19pandemic
AT tiwaskarmangesh hypoglycemiaatthetimeofcovid19pandemic
AT chawlapurvi hypoglycemiaatthetimeofcovid19pandemic
AT kalemayura hypoglycemiaatthetimeofcovid19pandemic
AT deshmanerajesh hypoglycemiaatthetimeofcovid19pandemic
AT sowanialpana hypoglycemiaatthetimeofcovid19pandemic